As Nektar Therapeutics (NKTR) Market Valuation Rose, Holder First Light Asset Management LLC Trimmed Stake by $8.94 Million

April 26, 2018 – By Marie Mckinney

Nektar Therapeutics (NASDAQ:NKTR) LogoInvestors sentiment decreased to 1.19 in 2017 Q4. Its down 0.21, from 1.4 in 2017Q3. It dropped, as 18 investors sold NKTR shares while 82 reduced holdings. 65 funds opened positions while 54 raised stakes. 150.36 million shares or 1.08% more from 148.76 million shares in 2017Q3 were reported. Cibc Asset Mgmt owns 5,415 shares or 0% of their US portfolio. Deutsche Bank & Trust Ag holds 0.01% or 370,002 shares. Rice Hall James And Associate Lc, California-based fund reported 1.03M shares. Federated Invsts Pa holds 0.22% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 1.28M shares. Artal Grp Inc reported 400,000 shares or 0.36% of all its holdings. Amundi Pioneer Asset Mngmt accumulated 189,100 shares. California State Teachers Retirement Systems stated it has 233,964 shares. Vident Invest Advisory Limited Company reported 21,339 shares stake. State Of Alaska Department Of Revenue reported 0.04% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Crow Point Ptnrs Ltd Llc invested in 0.01% or 539 shares. Piedmont Ltd Liability Co reported 0.04% stake. Nuveen Asset Llc invested 0% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). First Mercantile Trust Com has invested 0.06% in Nektar Therapeutics (NASDAQ:NKTR). Vanguard Group Incorporated, a Pennsylvania-based fund reported 14.81M shares. California Pub Employees Retirement Systems accumulated 233,379 shares or 0.02% of the stock.

Since December 13, 2017, it had 0 insider purchases, and 18 sales for $68.39 million activity. 502 shares were sold by Hora Maninder, worth $53,046 on Tuesday, April 10. Doberstein Stephen K also sold $201,212 worth of Nektar Therapeutics (NASDAQ:NKTR) shares. Shares for $288,382 were sold by Labrucherie Gil M. Another trade for 30,000 shares valued at $1.76M was made by KUEBLER CHRISTOPHER A on Tuesday, January 2. Nicholson John sold $404,664 worth of stock. 30,000 shares were sold by Lingnau Lutz, worth $3.05M.

First Light Asset Management Llc decreased its stake in Nektar Therapeutics (NKTR) by 30.1% based on its latest 2017Q4 regulatory filing with the SEC. First Light Asset Management Llc sold 151,452 shares as the company’s stock rose 80.22% while stock markets declined. The institutional investor held 351,741 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $21.01 million, down from 503,193 at the end of the previous reported quarter. First Light Asset Management Llc who had been investing in Nektar Therapeutics for a number of months, seems to be less bullish one the $13.29B market cap company. The stock decreased 2.27% or $1.92 during the last trading session, reaching $82.59. About 2.61 million shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 347.01% since April 26, 2017 and is uptrending. It has outperformed by 335.46% the S&P500.

First Light Asset Management Llc, which manages about $154.73M and $364.66M US Long portfolio, upped its stake in Nevro Corp by 95,999 shares to 155,904 shares, valued at $10.76 million in 2017Q4, according to the filing.

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on May, 8. They expect $-0.43 EPS, down 2.38 % or $0.01 from last year’s $-0.42 per share. After $-0.14 actual EPS reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts 207.14 % negative EPS growth.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

Among 8 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics has $125 highest and $35.0 lowest target. $91.75’s average target is 11.09% above currents $82.59 stock price. Nektar Therapeutics had 12 analyst reports since November 7, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, January 10 by Canaccord Genuity. The company was maintained on Monday, April 9 by Cowen & Co. Canaccord Genuity initiated the stock with “Buy” rating in Thursday, November 9 report. The company was maintained on Wednesday, November 8 by Jefferies. The rating was reinitiated by H.C. Wainwright on Monday, April 2 with “Buy”. The rating was maintained by PiperJaffray on Friday, April 13 with “Overweight”. The firm earned “Buy” rating on Thursday, March 29 by Mizuho. Roth Capital maintained the shares of NKTR in report on Monday, November 13 with “Buy” rating. The rating was maintained by Mizuho on Friday, April 6 with “Buy”.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.